findmyKOL
Clinical trialNCT05004727RecruitingPhase 4Interventional

Multi-Center PAMPA Study

SponsorNYU Langone HealthEnrollment176Psoriasis
View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

This is a multi-center (North-America), randomized, double-blind, placebo-controlled, wait-list, interventional, preventive trial of guselkumab in high-risk psoriasis patients compared to non-biologic standard of care. The primary objective of the proposed trial will be to test the hypothesis that a prolonged, unresolved skin inflammation coupled with musculoskeletal power-doppler ultrasound (MSKPDUS) abnormalities driven by IL-23 increase the risk for transition into PsA and that an intervention that targets one of these pivotal molecules (i.e., Guselkumab) will: 1. Diminish MSKPDUS findings at 24 weeks, and 2. Significantly reduce or prevent the emergence of synovio-enthesial phenotype at year 2.
clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

5 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

Canada
  • Memorial University

    St. John's, Newfoundland and Labrador, Canada

    Proton Rahman, MDWayne Gulliver, MD, FRCPC
    Recruiting
  • Women'S College Research Institute, University of Toronto

    Toronto, Ontario, Canada

    Jensen Yeung, MDLihi Eder, MD PhDVincent Piguet, MD PhD
    Recruiting
United States
  • Brigham and Women'S Hospital

    Boston, Massachusetts, United States

    Joseph Merola, MD, MMSc
    Recruiting
  • Nyu Langone Health

    New York, New York, United States

    Andrea Neimann, MD, MSCEAndrea Troxel, ScDJiyuan Hu, PhDJonathan Samuels, MDJose Scher, MDMichael Toprover, MDRebecca Haberman, MD, MSCI
    Recruiting
  • University of Rochester Medical Center (urmc)

    Rochester, New York, United States

    Christopher Ritchlin, MD, MPHFrancisco Tausk, MDRalf Thiele, MD
    Recruiting

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Guselkumab →Placebo
Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start
16 Feb 2022
Primary completion
31 Dec 2026
Completion
2 Nov 2028
Last update posted
30 Mar 2026
Registered enrollment
176
Registry id
NCT05004727
clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.